Scarica l'app Stockscreener
0.9638
0.61%
0.0058
Dopo l'orario di chiusura:
1.00
0.0362
+3.76%
Precedente Chiudi:
$0.958
Aprire:
$0.9478
Volume 24 ore:
173.49K
Relative Volume:
0.82
Capitalizzazione di mercato:
$68.44M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-1.2851
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
-0.66%
1M Prestazione:
-12.38%
6M Prestazione:
+28.22%
1 anno Prestazione:
-69.50%
Intervallo 1D:
$0.93
$1.02
Intervallo di 1 settimana:
$0.93
$1.02
Portata 52W:
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.9638 | 68.44M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc (NASDAQ: OVID) Drops -2.44 Percent In Recent Trading, What Questions Do You Have? - Stocks Register
Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest - MarketBeat
Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935 - Reuters
Fmr LLC Acquires 47,723 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Price Target at $4.04 - MarketBeat
Verition Fund Management LLC Makes New Investment in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
HC Wainwright Has Bullish Estimate for OVID FY2024 Earnings - MarketBeat
HC Wainwright Has Strong Forecast for OVID FY2024 Earnings - Defense World
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Ovid Therapeutics to Present Multiple Posters Supporting - GlobeNewswire
Ovid Therapeutics Unveils Breakthrough Epilepsy Treatment Data at Major Conference | OVID Stock News - StockTitan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Analysts - MarketBeat
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat
Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR
Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World
Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World
William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters
Ovid Therapeutics Inc (OVID) Quarterly 10-Q Report - Quartzy
William Blair Analysts Increase Earnings Estimates for OVID - MarketBeat
Ovid Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
US Penny Stocks To Watch This November 2024 - Simply Wall St
Ovid Therapeutics to Host Investor Event - GlobeNewswire
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat
Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace
Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents 2024 - Legal Service India
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com
Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):